• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Salient Pharmaceuticals

edit

Salient is a Texas-based company formed in 2007 to explore the pharmaceutical application of its proprietary composition of a rare, all-natural mineral. This composition has been proven to adsorb a range of toxins and inflammatory proteins commonly associated with diarrhea.

Salient’s compound, CASAD™, is envisioned to be a “platform” product effective across a spectrum of conditions from Cancer Therapy-Induced Diarrhea to infectious disease and chronic GI conditions. It also has the potential to be used as a rescue agent for other drugs with toxic side effects.

Recent Milestones

edit

• 
  Salient Pharmaceuticals added David Steakley as board of directors. (2/13/11)
  Posted 3/12/11 at 6:16am
• 
  Salient Pharmaceuticals received $2M in Venture Round funding. (1/29/10)
  Posted 1/29/10 at 8:25pm via finsmes.com
• 
  Salient Pharmaceuticals added Richard M. Scruggs as President and CEO.
  Posted 1/29/10 at 8:25pm
• 
  Salient Pharmaceuticals added Robert H. Carpenter as Chief Science Officer.
  Posted 1/29/10 at 8:25pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/30/10

Sources

1. Salient Pharmaceuticals Receives $2M Funding to Develop Treatment for Cancer Therapy Side Effect (finsmes.com) [edit]